Free Trial

Propanc Biopharma Q2 2024 Earnings Report

Propanc Biopharma logo
$0.0002 0.00 (-33.33%)
As of 01/21/2025 03:30 PM Eastern

Propanc Biopharma EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Propanc Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Propanc Biopharma Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Propanc Biopharma Earnings Headlines

Propanc Biopharma Inc (PPCB)
Stunning Trump Manhattan Project Now Underway
Just as I predicted, President Trump announced his #1 move during his first 100 days... His allies are calling it Trump’s Manhattan Project.
VTXB Vortex Brands Co.
Propanc Biopharma, Inc. (PPCB)
See More Propanc Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Propanc Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Propanc Biopharma and other key companies, straight to your email.

About Propanc Biopharma

Propanc Biopharma (OTCMKTS:PPCB), a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

View Propanc Biopharma Profile

More Earnings Resources from MarketBeat